Group items matching

in title, tags, annotations or url

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

To continue making safe and effective topical semisolid drug products available to the American public, it is essential that FDA's regulatory science, as well as best practices in the pharmaceutical industry, are informed by the most current understanding of the product quality attributes that are potentially critical to the therapeutic performance of topical semisolid dosage forms. The scope of this project is to characterize all measurable physical/chemical qualities of different dosage forms of semisolid topical drug products, identify appropriate methodologies for measuring each of these quality attributes, characterize formulation and manufacturing parameters that alter the arrangement of matter in the dosage form as measured by specific quality attributes, and utilize in vitro and/or in vivo measures of product performance to correlate variations in critical quality attributes with a failure mode for a drug product.  

The goal of the Energy for Sustainability program is to support fundamental engineering research that will enable innovative processes for the sustainable production of electricity and fuels, and for energy storage. Processes for sustainable energy production must be environmentally benign, reduce greenhouse gas production, and utilize renewable resources. Research projects that stress molecular level understanding of phenomena that directly impacts key barriers to improved system level performance (e.g. energy efficiency, product yield, process intensification) are encouraged. Proposed research should be inspired by the need for economic and impactful conversion processes. All proposals should include in the project description, how the proposed work, if successful, will improve process realization and economic feasibility and compare the proposed work against current state-of-the-art. Highly integrated multidisciplinary projects are encouraged.

he Electrochemical Systems program is part of the Chemical Process Systems cluster, which includes also 1) Catalysis; 2) Molecular Separations; and 3) Process Systems, Reaction Engineering, and Molecular Thermodynamics. The goal of the Electrochemical Systems program is to support fundamental engineering research that will enable innovative processes involving electro- or photochemistry for the sustainable production of electricity, fuels, and chemicals. Processes for sustainable energy and chemical production must be scalable, environmentally benign, reduce greenhouse gas production, and utilize renewable resources. Research projects that stress fundamental understanding of phenomena that directly impact key barriers to improved system or component-level performance (e.g., energy efficiency, product yield, process intensification) are encouraged. Processes for energy storage should address fundamental research barriers for the applications of renewable electricity storage or for transport propulsion

The Electrochemical Systems program is part of the Chemical Process Systems cluster, which also includes: 1) the Catalysis program; 2) the Interfacial Engineering program; and 3) the Process Systems, Reaction Engineering, and Molecular Thermodynamics program. The goal of the Electrochemical Systems program is to support fundamental engineering research that will enable innovative processes involving electro- or photochemistry for the sustainable production of electricity, fuels, and chemicals. Processes for sustainable energy and chemical production must be scalable, environmentally benign, reduce greenhouse gas production, and utilize renewable resources. Research projects that stress fundamental understanding of phenomena that directly impact key barriers to improved system or component-level performance (for example, energy efficiency, product yield, process intensification) are encouraged. Processes for energy storage should address fundamental research barriers for the applications of renewable electricity storage or for transport propulsion. For projects concerning energy storage materials, proposals should involve hypotheses that involve device or component performance characteristics that are tied to fundamental understanding of transport, kinetics, or thermodynamics. Advanced chemistries are encouraged. Proposed research should be inspired by the need for economic and impactful conversion processes. All proposal project descriptions should address how the proposed work, if successful, will improve process realization and economic feasibility and compare the proposed work against current state of the art. Highly integrated multidisciplinary projects are encouraged.

The purpose of the IR-4 program is to enable the crop protection industry to provide safe, effective, and economical crop protection products for growers and consumers of minor/specialty crops. The crop protection industry cannot justify the costs associated with the research and development, registration, production, and marketing of crop protection products for minor/specialty crops due to the smaller market base and limited sales potential. The IR-4 program provides the assistance needed to ensure that new and more effective crop protection products are developed and made available to minor/specialty crop producers. These efforts require effective collaborations among federal agencies, the crop protection industry, and land-grant colleges and universities.

Genomic Science program supports basic research aimed at identifying the foundational principles that drive biological systems. These principles govern the translation of the genetic code into integrated networks of proteins, enzymes, regulatory elements, and metabolite pools that are the functional processes of organisms including microbes and multispecies communities relevant to DOE missions in energy and the environment. To address the DOE mission in sustainable Bioenergy development, the Genomic Science program brings omics-driven tools of modern systems biology to bear on the challenges associated with microbial production of advanced Biofuels and Bioproducts.Developing an increased understanding of how biological systems function and translating that knowledge to enhance the production capabilities of microbes and plants forms the basis of DOE's mission in sustainable Bioenergy. To harness the biosynthetic processing power of the microbial world for advanced Biofuels and Bioproducts production, an expanded set of platform organisms with appropriate metabolic capabilities and stress tolerance characteristics with a suite of modification tools will need to be developed. To foster this development, the DOE-BER Genomic Science program supports research aimed at understanding the principles that govern the functional properties of bioenergy relevant organisms at the genomic scale.

The goal of the Energy for Sustainability program is to support fundamental engineering research that will enable innovative processes and solutions for the sustainable production of electricity and fuels, and energy storage. Processes for sustainable energy production must be environmentally benign, reduce greenhouse gas production, and utilize renewable resources. 

The goal of the Catalysis and Biocatalysis program is to drive innovation in the production of the myriad of goods and services that are derived from catalyst-driven reactions.  Research in this program encompasses a blend of fundamental, engineering research drivers that are interdisciplinary in nature.  Studies should focus on the catalysis of one or more use-inspired chemical reactions with products including fuels, energy, feedstocks, fine chemicals, bulk chemicals and specialized materials.  While proposals will be accepted in any of the above areas, an emphasis will be placed on proposals addressing the significant existing challenges in producing products for the service of mankind.

Bioequivalence studies that compare a reference formulation to an investigational formulation are typically conducted in healthy adult volunteers and occasionally are conducted in patients. Some populations have unique physical, biological, and physiological considerations that are not reflected by healthy volunteers or by the typical patient for whom a drug is indicated. Physicians have expressed concerns about generic drug substitution (especially for narrow therapeutic index drugs) in special patient populations whose experience with a drug may not be represented by those in whom bioequivalence studies are conducted. For instance, for products that do not have age-appropriate formulations (e.g., formulations do not differ by age of patient), the use of generic products under "off-label" practice patterns in special populations such as crushing or dissolving tablets in liquid for pediatric patients may influence their equivalence to brand name products. Special populations include, but are not limited to, pediatric patients, elderly patients who take multiple medications, women (particularly those who are pregnant), racial/ethnic minorities, and/or individuals with impaired kidney or liver function.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-395.

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. The mission of the CounterACT Program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scaleable manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 - see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan.

Using its strength in glycoscience, the client wishes to achieve the following FCH- and s-FCH-related goals with a potential partner to continue to supply the world with innovative pharmaceuticals/medical devices in this field: Supply pharmaceuticals/medical devices that meet unmet medical needs Specialized areas/diseases: Diseases of locomotive organs, ophthalmic diseases, and diseases of the mucous membrane in the mouth, esophagus, gastrointestinal tract, etc. Supply products that cannot be replaced by other products or competitor's products, using the client's strength in glycoscience

In 2010, NSF established the Science, Engineering, and Education for Sustainability (SEES)1 investment area to lay the research foundation for decision capabilities and technologies aimed at mitigating and adapting to environmental changes that threaten sustainability. Some SEES investments advanced a systems-based approach to understanding, predicting, and reacting to stress upon, and changes in, the linked natural, social, and built environments. In this context, the importance of understanding the interconnected and interdependent systems involving food, energy, and water (FEW) has emerged. The NSF aims to specifically focus on advancing knowledge of the nitrogen and phosphorus cycles; the production and use of fertilizers for food production; and the detection, separation, and reclamation/recycling of nitrogen- and phosphorus-containing species in and from complex aqueous environments.

In 2010, NSF established the Science, Engineering, and Education for Sustainability (SEES)1 investment area to lay the research foundation for decision capabilities and technologies aimed at mitigating and adapting to environmental changes that threaten sustainability. Some SEES investments advanced a systems-based approach to understanding, predicting, and reacting to stress upon, and changes in, the linked natural, social, and built environments. In this context, the importance of understanding the interconnected and interdependent systems involving food, energy, and water (FEW) has emerged. The NSF aims to specifically focus on advancing knowledge of the nitrogen and phosphorus cycles; the production and use of fertilizers for food production; and the detection, separation, and reclamation/recycling of nitrogen- and phosphorus-containing species in and from complex aqueous environments.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

This Program encourages research on processes and production systems based on computation, modeling and simulation, use of process metrology, sensing, monitoring, and control, and assessment of product (nanomaterial, nanostructure, nanodevice or nanosystem) quality and performance. The Program seeks to explore transformative approaches to nanomanufacturing, including but not limited to: micro-reactor and micro-fluidics enabled nanosynthesis, bio-inspired nanomanufacturing, manufacturing by nanomachines, additive nanomanufacturing, hierarchical nanostructure assembly, continuous high-rate nanofabrication such as roll-to-roll processing or massively-parallel large-area processing, and modular manufacturing platforms for nanosystems. 

Fundamental research topics of interest in SusChEM include the replacement of rare, expensive, and/or toxic chemicals/materials with earth-abundant, inexpensive, and benign chemicals/materials; recycling of chemicals/materials that cannot be replaced; development of non-petroleum based sources of important raw materials; the elimination of waste products and enhancement in efficiencies of chemical reactions and processes; discovery of new separation science that will facilitate recycling and production of valuable chemicals/materials; and development and characterization of low cost, sustainable and scalable-manufactured materials with improved properties.

Examples of fundamental research topics of interest in SusChEM include the replacement of rare, expensive, and/or toxic chemicals/materials with earth-abundant, inexpensive, and benign chemicals/materials; recycling of chemicals/materials that cannot be replaced; development of non-petroleum based sources of important raw materials; chemicals/materials for food and/or water sustainability; the elimination of waste products and enhancement in efficiencies of chemical reactions and processes; discovery of new separation science that will facilitate recycling and production of valuable chemicals/materials; and development and characterization of low cost, sustainable and scalable-manufactured materials with improved properties.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for projects focused on development and/or production of diagnostics that will enable rapid, sensitive, specific, culture-independent detection of high-priority antimicrobial-resistant Gram-negative bacterial pathogens. This FOA is focused on select healthcare-associated bacteria where resistance compromises effective treatment, including: Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and extra-intestinal pathogenic Escherichia coli. Applications must include a Product Development Strategy and demonstrate substantive participation by at least one industrial participant.

The Centers of Research Excellence in Science and Technology (CREST) program provides support to enhance the research capabilities of minority-serving institutions (MSI) through the establishment of centers that effectively integrate education and research. CREST promotes the development of new knowledge, enhancements of the research productivity of individual faculty, and an expanded presence of students historically underrepresented in science, technology, engineering, and  mathematics (STEM) disciplines. HBCU-RISE awards specifically target HBCUs to support the expansion of institutional research capacity as well as the production of doctoral students, especially those from groups underrepresented in STEM,  at those institutions.